4.7 Article

PEG-Bottlebrush Stabilizer-Based Worm-like Nanocrystal Micelles with Long-Circulating and Controlled Release for Delivery of a BCR-ABL Inhibitor against Chronic Myeloid Leukemia (CML)

Journal

PHARMACEUTICS
Volume 14, Issue 8, Pages -

Publisher

MDPI
DOI: 10.3390/pharmaceutics14081662

Keywords

drug nanocrystal; stabilizer; micelle; BCR-ABL; chronic myeloid leukemia (CML)

Funding

  1. National Natural Science Foundation of China [82103976, 82173671]
  2. Anhui Provincial Natural Science Foundation [2108085J42, 2108085QH377]
  3. Frontier Science Key Research Program of CAS [QYZDB-SSW-SLH037]
  4. CASHIPS Director's Fund [YZJJ2021QN38]
  5. Leading Talent Program of Hefei [2018-1-006]
  6. Youth Innovation Promotion Association of CAS [Y202088]

Ask authors/readers for more resources

Drug nanocrystals, a common drug delivery system, have the potential to enhance the delivery of poorly water-soluble drugs. However, their rapid clearance and uncontrolled drug release limit their effectiveness. In this study, an amphiphilic co-polymer was synthesized as a stabilizer to fabricate high-drug-loading nanocrystal micelles. These micelles exhibited small size, high drug loading, and controlled release in vitro, as well as long circulation and high drug accumulation in vivo. This research provides new possibilities for the development of more efficient nanocrystal-based injection formulations and the potential clinical application of a CML candidate drug.
Drug nanocrystals, one of most common drug delivery systems, enable the delivery of poorly water-soluble drugs with high drug loading and enhanced dissolution. The rapid clearance and uncontrolled drug release of drug nanocrystals limit their delivery efficiency and clinical application. Herein, an amphiphilic co-polymer, poly oligo(ethylene glycol) methacrylate-b-poly(styrene-co-4-formylphenyl methacrylate) (POEGMA-b-P (St-co-FPMA), PPP), characterized by a hydrophilic part with bottlebrush-like oligo(ethylene glycol) methacrylate (OEGMA) side chains, was synthesized as stabilizers to fabricate a high-drug-loading nanocrystal micelle (053-PPP NC micelle) using the chronic myeloid leukemia (CML) drug candidate N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053 or 053) as a model drug. The 053-PPP NC micelle was characterized and subjected to in vitro and in vivo studies. It featured a worm-like shape of small size, high drug loading (similar to 50%), high colloidal stability, and controlled release in vitro. The presence of the 053-PPP NC micelle resulted in a long-circulation property and a much higher AUC. The 053-PPP NC micelle induced higher accumulation in the tumor tissues under multiple continuous administration. For in vivo efficacy, the 053-PPP NC micelle with a longer dosing interval (96 h), beneficial for improving patient adherence, demonstrated superiority to the 053-F127 NC. The proposed stabilizer PPP and the 053-PPP NC micelle with high drug loading enables drug delivery with long circulation and controlled release of drugs. It is also promising for the development of more efficient nanocrystal-based intravenous injection formulations for poorly water-soluble drugs. It might also offer new possibilities for potential clinical application of the CML candidate drug 053.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available